<DOC>
	<DOC>NCT02481830</DOC>
	<brief_summary>The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.</brief_summary>
	<brief_title>Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Histologically or cytologically confirmed small cell lung cancer (SCLC) Subjects with either limited or extensive disease stage at the initial diagnosis Must have recurrence or progression after platinumbased firstline chemotherapy or chemoradiation therapy for the treatment of limited or extensive disease stage SCLC Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Untreated or symptomatic central nervous system (CNS) metastases Prior therapy with antiPD1, antiPDL1, antiPDL2, antiCD137, or antiCTLA4 antibody Inadequate hematologic or hepatic function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>